Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699278 | 0.79 | — | — | |
| SCHEMBL15912161 | 0.78 | CA1 (0.40) | CA1CA2TSHR | |
| SCHEMBL15912157 | 0.78 | USP2 (0.30) | TSHR | |
| SCHEMBL15912174 | 0.77 | — | — | |
| SCHEMBL15912172 | 0.77 | — | — | |
| SCHEMBL15912196 | 0.74 | CA1 (0.37) | CA1CA2TSHR | |
| SCHEMBL192086 | 0.74 | TSHR (0.48) | CA1CA2TSHR | |
| SCHEMBL23732942 | 0.74 | — | — | |
| SCHEMBL778735 | 0.70 | — | — | |
| SCHEMBL15966600 | 0.70 | TSHR (0.43) | CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | claimed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2536275-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM Research Foundation, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011103189-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010144959-A1 | ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-12-23 | — | — | WO | disclosed |
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-0906333-B1 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | MEDIVIR UK LTD (GB) | 2001-07-25 | — | — | EP | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6034066-A | ANTIALLERGENS | PEPTIDE THERAPEUTICS LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0906333-A2 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997040065-A2 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | CA1 2595/4885CA2 3357/4885TSHR 814/4885 |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | PGLS, RRS1, MRPL21 | CA1 4757/4885CA2 4044/4885TSHR 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.